Fact CheckerSign in

NCT07011095Not yet recruitingEarly phase 1

DOAC or VKA in Patients With AF and Stroke While on DOAC - a Pilot Trial

A Pilot Trial to Assess the Feasibility of a Multicentre, Phase IV, Prospective, Randomized, Open-label, Two-arm Study With Blinded-endpoint Evaluation to Investigate Vitamin K Antagonist (VKA) Therapy Compared With Direct Oral Anticoagulant (DOAC) Therapy in Male and Female Participants With Atrial Fibrillation and Recent Ischemic Stroke While on a DOAC

Source: ClinicalTrials.gov · Last updated 8 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

People with atrial fibrillation who have a stroke while receiving a DOAC are at increased risk of experiencing another stroke. Physicians do not know the best medication to prevent another stroke in this group of people. Options include continuing the same DOAC, switching to another DOAC or switching to warfarin. The investigators of the SWITCH-AF trial are trying to find out whether switching to warfarin or continuing a DOAC is better for preventing stroke. The purpose of this study, called a pilot study, is to test the study plan and to find out whether enough participants will join a larger study that answers the question. A pilot study involves a small number of participants and it is not expected to tell us which treatment is better.

Status (registry)
Not yet recruiting
Phase (registry)
Early phase 1
Study type
Interventional
Enrollment
100 (estimated)
First submitted
27 May 2025
Start date
3 Sept 2025
Primary completion date
3 Feb 2027
Lead sponsor
Population Health Research Institute
NCT number
NCT07011095

What you commit to

  • Study type: Interventional · Early phase 1
  • Planned participants: 100
  • From 3 Sept 2025 to the primary completion date, 3 Feb 2027
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Patient is on chronic hemodialysis or likely to need renal replacement therapy during the course of the trial.

Other illness

  • There is strong evidence for the qualifying stroke event to be associated with permanent discontinuation of DOAC therapy (for any reason)
  • History of intracranial bleeding.

Other

  • Patient is unable or unwilling to take oral anticoagulation

Who the study is looking for

  • Written informed consent provided.
  • Age \>18 years.
  • Documented history of AF or atrial flutter.
  • Ischemic stroke while on a DOAC within 14 days prior to enrollment identified on imaging.
  • In the opinion of the investigator, it is safe to initiate oral anticoagulation with either a VKA or a DOAC within 24 hours of randomization-

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.